SUPPORTING INFORMATION FOR:

Potent combretastatin A-4 analogues containing quinoline: Design, Synthesis, antiproliferative, and anti-tubulin activity

Tarek S. Ibrahim [1,2,*], Mohamed M. Hawwas [3], Azizah M. Malebari [1], Ehab S. Taher [3], Abdelsattar M. Omar [1,4], Niamh M. O'Boyle [5], Eavan McLoughlin [5], Zakaria K. Abdel-Samii [2], Yaseen A.M.M. Elshaier [6]

[1] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; tmabrahem@kau.edu.sa (T.S.I.); amelibary@kau.edu.sa (A.M.M.); asmansour@kau.edu.sa (A.M. O)

[2] Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt; tmabrahem@kau.edu.sa (T.S.I.); zakariaabdelsamii@yahoo.com (Z.K.A)

[3] Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt. mohhawwas@yahoo.com (M.M.H); ehabtaher@azhar.edu.eg (E.S.T)

[4] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt. asmansour@kau.edu.sa (A.M. O)

[5] School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, Ireland. niamh.oboyle@tcd.ie (N.M.O); mclougea@tcd.ie (E.M)

[6] Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, 32958 Menoufia, Egypt. yaseenorganic@yahoo.com (Y.A.M.M.E)

*Corresponding authors:

Tarek S. Ibrahim, Associate Professor, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.

Tel.: +966535846571

E-mail address: tmabrahem@kau.edu.sa, tarekeldeeb1976@yahoo.com

CONTENTS

Figure S1; ^{1}H NMR for compound 19a



Figure S2; ^{13}C NMR for compound 19a



Figure S3; ^{1}H NMR for compound 19b



Figure S4; ^{13}C NMR for compound 19b



Figure S5; ^{1}H NMR for compound19c



Figure S6; ^{13}C NMR for compound 19c



Figure S7; ^{1}H NMR for compound 19d



Figure S8; ^{13}C NMR for compound 19d



Figure S9; ^{1}H NMR for compound 19e



Figure S10; ^{13}C NMR for compound 19e



Figure S11; ^{1}H NMR for compound 19f



Figure S12; ^{13}C NMR for compound 19f



Figure S13; ^{1}H NMR for compound 19g



Figure S14; ^{13}C NMR for compound 19g



Figure S15; ^{1}H NMR for compound 19h



Figure S16; ^{13}C NMR for compound 19h



Figure S17; ^{1}H NMR for compound 19i



Figure S18; ^{13}C NMR for compound 19i



Figure S19; ^{1}H NMR for compound 19j



Figure S20; ^{13}C NMR for compound 19j



Figure S21; ^{1}H NMR for compound 20a



Figure S22; ^{13}C NMR for compound 20a



Figure S23; ^{1}H NMR for compound 20b



Figure S24; ^{13}C NMR for compound 20b



Figure S25; ^{1}H NMR for compound 20c



Figure S26; ^{13}C NMR for compound 20c



Figure S27; ^{1}H NMR for compound 20d



Figure S28; ^{13}C NMR for compound 20d



Figure S29; ^{1}H NMR for compound 20e



Figure S30; ^{13}C NMR for compound 20e



Figure S31; ^{1}H NMR for compound 20f



Figure S32; ^{13}C NMR for compound 20f



Figure S33; ^{1}H NMR for compound 20g



Figure S34; ^{13}C NMR for compound 20g



Figure S35; ^{1}H NMR f or compound 20h



Figure S36; ^{13}C NMR for compound 20h



Figure S37; ^{1}H NMR for compound 20i



Figure S38; ^{13}C NMR for compound 20i



Figure S39; ^{1}H NMR for compound 20j



Figure S40; ^{13}C NMR for compound 20j





Figure S41. **A.** Quinoline **19b** (yellow) and CA-4 (cyan) docked at the colchicine-binding site of tubulin in co-crystal 1SAO. **B.** Quinoline **20c** (pink) and DAMA-colchicine (green) docked at the colchicine-binding site of tubulin in co-crystal 1SAO. **C.** Quinoline **9=20g** (red) and CA-4 (cyan) docked at the colchicine-binding site of tubulin in co-crystal 1SAO. Protein residues removed on right for clarity. (red = oxygen, grey = hydrogen).



Figure S42. 2D Ligand Interaction Schematic for **19b** as generated by MOE



Figure S43. 2D Ligand Interaction Schematic for **20c** as generated by MOE



Figure S44. 2D Ligand Interaction Schematic for **20g** as generated by MOE